• Extendicare has received approval for a normal course issuer bid (NCIB)
  • The company may cancel up to 7,829,630 of its common shares between June 30, 2022, and June 29, 2023
  • Shares purchased under the NCIB will be cancelled
  • The NCIB will provide the company with additional flexibility to manage capital
  • Extendicare is a leading provider of care and services for seniors across Canada
  • Extendicare Inc. (EXE) opened trading at C$6.99

Extendicare has received approval from the Toronto Stock Exchange for a normal course issuer bid (NCIB). 

The company may purchase up to 7,829,630 of its common shares between June 30, 2022 and June 29, 2023. Daily purchases will be limited to 53,068 common shares, other than block purchase exceptions.

Purchases will be made through the facilities of the TSX and/or through alternative Canadian trading systems, in accordance with TSX rules. Any common shares purchased by the company under the NCIB will be cancelled.

The company believes that the NCIB will provide additional flexibility to manage capital. 

Extendicare is a leading provider of care and services for seniors across Canada, operating under the Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Partner Network brands.

Extendicare Inc. (EXE) opened trading at C$6.99

More From The Market Online

Reliq Health expands contract with U.S. health group

Reliq Health Technologies (TSXV:RHT) reveals it has expanded an existing contract with a large U.S. health group.

Telo Genomics and Emery Pharma collaborate

Telo Genomics (TSXV:TELO) collaborates with Emery Pharma to enhance cellular and molecular bioanalytical solutions for clinical research.

UniDoc brings AI to ER patients

UniDoc (CSE:UDOC) expands its AI partnership with DocBox, further integrating predictive analytics into emergency room operations.